» Articles » PMID: 22581828

Activation of the Notch1/STAT3/Twist Signaling Axis Promotes Gastric Cancer Progression

Overview
Journal Carcinogenesis
Specialty Oncology
Date 2012 May 15
PMID 22581828
Citations 78
Authors
Affiliations
Soon will be listed here.
Abstract

Gastric carcinoma is one of the most common malignancies and a lethal cancer in the world. Notch signaling and transcription factors STAT3 (signal transducer and activator of transcription 3) and Twist regulate tumor development and are critical regulators of gastric cancer progression. Herein, the relationship among Notch, STAT3 and Twist pathways in the control of gastric cancer progression was studied. We found that Twist and phosphorylated STAT3 levels were promoted by the activated Notch1 receptor in human stomach adenocarcinoma SC-M1, embryonic kidney HEK293 and erythroleukemia K562 cells. Notch1 signaling dramatically induced Twist promoter activity through a C promoter binding factor-1-independent manner and STAT3 phosphorylation. Overexpression of Notch1 receptor intracellular domain (N1IC) enhanced the interaction between nuclear STAT3 and Twist promoter in cells. Gastric cancer progression of SC-M1 cells was promoted by N1IC through STAT3 phosphorylation and Twist expression including colony formation, migration and invasion. STAT3 regulated gastric cancer progression of SC-M1 cells via Twist. N1IC also elevated the progression of other gastric cancer cells such as AGS and KATO III cells through STAT3 and Twist. The N1IC-promoted tumor growth and lung metastasis of SC-M1 cells in mice were suppressed by the STAT3 inhibitor JSI-124 and Twist knockdown. Furthermore, Notch1 and Notch ligand Jagged1 expressions were significantly associated with phosphorylated STAT3 and Twist levels in gastric cancer tissues of patients. Taken together, these results suggest that Notch1/STAT3/Twist signaling axis is involved in progression of human gastric cancer and modulation of this cascade has potential for the targeted combination therapy.

Citing Articles

NOTCH1 promotes the elevation of GM-CSF and IL-6 through the EZH2/STAT3 pathway to facilitate the fibrotic state of the myocardium in DLBCL.

Zhang H, Dong W, Zhang L, Ma B, Wang J, Shen Y PLoS One. 2025; 20(2):e0316923.

PMID: 39951437 PMC: 11828423. DOI: 10.1371/journal.pone.0316923.


Deregulation of expression by promoter methylation in gastrointestinal cancers.

Alfahed A Saudi J Biol Sci. 2024; 31(8):103842.

PMID: 39479535 PMC: 11385410. DOI: 10.1016/j.sjbs.2023.103842.


Induction, growth, drug resistance, and metastasis: A comprehensive summary of the relationship between STAT3 and gastric cancer.

Chen M, Wang T, Tian D, Hai C, Qiu Z Heliyon. 2024; 10(18):e37263.

PMID: 39309860 PMC: 11416542. DOI: 10.1016/j.heliyon.2024.e37263.


Notch signaling pathway in cancer: from mechanistic insights to targeted therapies.

Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S Signal Transduct Target Ther. 2024; 9(1):128.

PMID: 38797752 PMC: 11128457. DOI: 10.1038/s41392-024-01828-x.


Oncogenic STAT Transcription Factors as Targets for Cancer Therapy: Innovative Strategies and Clinical Translation.

Wang W, Lopez McDonald M, Hariprasad R, Hamilton T, Frank D Cancers (Basel). 2024; 16(7).

PMID: 38611065 PMC: 11011165. DOI: 10.3390/cancers16071387.